SELLAS Life Sciences Announces Recommendation Of Independent Data Monitoring Committee Following Completion Of Enrollment In REGAL Phase 3 Study

SELLAS Life Sciences Group Inc -3.51%

SELLAS Life Sciences Group Inc




– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications –


– IDMC Will Convene Again Ahead of Scheduled IDMC Charter Meeting –

– Next Efficacy and Safety Assessment of All REGAL Patients (n=127) in June 2024 –

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via